Herbal medicine shows potential to treat cancer

Researchers from King Abdullah University of Science and Technology (KAUST) have been searching locally for plants that have potential for use to combat cancer. Now, three plants used for traditional medicine in Saudi Arabia are shown to be worthy of further investigation for anticancer properties. Cancer is a leading cause of illness and death worldwide. In 2015, the World Health Organization (WHO) recorded 8.8 million cancer-related deaths, but almost twice as many cases are diagnosed each year. And the WHO predict that the number of cancer diagnoses is likely to continue to increase by about 70% for at least the next two decades due to growing longevity.

Seeking to expand the armory of cancer treatments - especially ones that are simple and inexpensive to manufacture - a team led by Timothy Ravasi and Christian Voolstra from KAUST has investigated the biological potential (bioactivity) of a range of plants used locally in traditional medicine.

Use of herbal medicines is common in Saudi Arabia, explains Ravasi's PhD student, Dina Hajjar. "However, there are almost no scientific studies," says Hajjar. "Saudi people tend to use information inherited from their families to decide about these plants without validated knowledge of their biological or chemical activity."

The team initially investigated 52 plants before they homed in on three plants that showed promise - Juniperus phoenicea (known in herbal medicine as Arar or Phoenican juniper), Anastatica hierochuntica (known as Kaff Maryam or the Jericho rose) and Citrullus colocynthis (known as Hanzal or bitter cucumber).

The team used cell-based phenotypic profiling via imaging-based high-content screening to assess anticancer activity. This approach followed a technique developed in 2016 by Stephan Kremb and Christian Voolstra that uses a comprehensive marker panel with standardized settings - an efficient process that could potentially be easily adopted by other laboratories. This meant the team compared the cytological profiles of fractions taken from the plants with a set of reference compounds with established mechanisms of action.

This enabled the team to show, for the first time, that these three plants contain potent anticancer substances - topoisomerase inhibitors, which are compounds that can block the topoisomerase enzymes that control changes in DNA - that could be used to develop novel anticancer inhibitors.

There are many steps, however, before these compounds are properly tested and available for clinical treatments for cancer. "The active compounds identified in the study will need to be evaluated and better characterized," says Hajjer. "Also, active compounds need to be synthesized and tested in vivo."

This study proves the power of using imaging-based high-content screening in revealing information about the bioactivity of unknown natural resources. Hajjar adds that it also highlights the opportunity for more exciting discoveries amongst the natural resources of Saudi Arabia.

Hajjar D, Kremb S, Sioud S, Emwas AH, Voolstra CR, Ravasi T.
Anti-cancer agents in Saudi Arabian herbals revealed by automated high-content imaging.
PLoS One. 2017 Jun 13;12(6):e0177316. doi: 10.1371/journal.pone.0177316.

Most Popular Now

FDA approves Vosevi for Hepatitis C

The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mil...

Green tea ingredient may ameliorate memory impairm…

A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active compone...

New way found to boost immunity in fight cancer an…

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemo...

Amgen and Array BioPharma announce preclinical lic…

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders...

Merck and Pfizer collaborate with Corning

Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging ...

One minute of running per day associated with bett…

A single minute of exercise each day is linked to better bone health in women, new research shows. Scientists from the University of Exeter and the University of Leiceste...

Americans say discussions about clinical trials sh…

An overwhelming majority of Americans (86%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their st...

AstraZeneca and Merck establish strategic oncology…

AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered a global strategic oncology collaboration to ...

27 Phase III and 8 Phase II Alzheimer's drugs on t…

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheime...

Johnson & Johnson announces encouraging first-…

Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Compani...

How physical exercise prevents dementia

Numerous studies have shown that physical exercise seems beneficial in the prevention of cognitive impairment and dementia in old age. Now researchers at Goethe Universit...

New drug may treat and limit progression of Parkin…

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]